Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966740 · ClinicalTrials.gov registry record
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
A clinical trial, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- 5
- Enrollment target
NCT05966740 is a clinical trial that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 5 participants.
The verdict
NCT05966740 was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2025-04-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966740
The ClinicalTrials.gov registry entry for NCT05966740 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05966740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05966740 about?
NCT05966740 is a clinical study titled "A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot". The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
What is the current status of trial NCT05966740?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2024-04-19. Estimated completion is 2025-04-28.
Who is sponsoring clinical trial NCT05966740?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.